2025-04-01 18:14:38
Latest Post
Godawari Power And Ispat Ltd announces temporary suspension of operations at Boria Tibu
Lloyds Metals and Energy records the highest-ever Sponger iron Production
MMRFIC Collaborates with IITM for the development of Secure SoC IP
Josts Engineering Company Ltd announces Exclusive Distribution Agreement for 'Zowell' Brand Warehouse Material Handling Equipment in India
Eris Lifesciences designates Gopal Agrawal and Nita Borkar in leadership roles
Stock Report
Jagsonpal Pharmaceuticals Ltd reports rise in Q2FY23 net profit to Rs. 10.41 crores
Posted On : 2022-11-10 19:59:44( TIMEZONE : IST )
Jagsonpal Pharmaceuticals Limited has reported Standalone financial results for the period ended September 30, 2022.
Financial Results (Q2 FY2023) - QoQ Comparison
The company has reported total income of Rs. 61.6469 crores during the period ended September 30, 2022 as compared to Rs. 60.9104 crores during the period ended June 30, 2022.
The company has posted net profit / (loss) of Rs. 10.4123 crores for the period ended September 30, 2022 as against net profit / (loss) of Rs. 2.9216 crores for the period ended June 30, 2022.
The company has reported EPS of Rs. 3.97 for the period ended September 30, 2022 as compared to Rs. 1.12 for the period ended June 30, 2022.
| Financials | Q2 FY2023 | Q1 FY2023 | % Change |
| Total Income | ₹ 61.6469 crs | ₹60.9104 crs |  1.21% |
| Net Profit | ₹10.4123 crs | ₹2.9216 crs | 256.39% |
| EPS | ₹3.97 | ₹1.12 | 254.46% |
Financial Results (Q2 FY2023) - YoY Comparison
The company has reported total income of Rs. 61.6469 crores during the period ended September 30, 2022 as compared to Rs.58.6779 crores during the period ended September 30, 2021.
The company has posted net profit / (loss) of Rs.10.4123 crores for the period ended September 30, 2022 as against net profit / (loss) of Rs.6.5640 crores for the period ended September 30, 2021.
The company has reported EPS of Rs.3.97 for the period ended September 30, 2022 as compared to Rs.2.51 for the period ended September 30, 2021.
| Financials | Q2 FY2023 | Q2 FY2022 | % Change |
| Total Income | ₹ 61.6469 crs | ₹58.6779 crs | 5.06% |
| Net Profit | ₹10.4123 crs | ₹6.5640 crs | 58.63% |
| EPS | ₹3.97 | ₹2.51 | 58.17% |
Financial Results (Half Year Ended FY2023) - YoY Comparison
The company has reported total income of Rs.122.5573 crores during the 6 Months period ended September 30, 2022 as compared to Rs.113.5545 crores during the 6 Months period ended September 30, 2021.
The company has posted net profit / (loss) of Rs.13.3339 crores for the 6 Months period ended September 30, 2022 as against net profit / (loss) of Rs.13.1443 crores for the 6 Months period ended September 30, 2021.
The company has reported EPS of Rs.5.09 for the 6 Months period ended September 30, 2022 as compared to Rs.5.02 for the 6 Months period ended September 30, 2021.
| Financials | Half Year Ended FY2023 | Half Year Ended FY2022 | % Change |
| Total Income | ₹122.5573 crs | ₹113.5545 crs | 7.93% |
| Net Profit | ₹13.3339 crs | ₹13.1443 crs | 1.44% |
| EPS | ₹5.09 | ₹5.02 | 1.39% |
Shares of Jagsonpal Pharmaceuticals Limited was last trading in BSE at Rs. 349.90 as compared to the previous close of Rs. 338.35. The total number of shares traded during the day was 3425 in over 312 trades.
The stock hit an intraday high of Rs. 353.25 and intraday low of 332.00. The net turnover during the day was Rs. 1191290.00.
